Company news

Patrys Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Appendix 4C - Quarterly - 30 September 2026

October 28, 2026

Appendix 4C - Quarterly - 30 September 2026

October 28, 2026

RLS-2202 Phase 1a Trial Advances to Cohort 2

October 21, 2026

RLS-2202 Phase 1a Trial Advances to Cohort 2

October 21, 2026

Investor Presentation

October 12, 2026

Investor Webinar

October 5, 2026

Appendix 4E Variance Report

September 28, 2026

First Participants Dosed in RLS-2202 Phase 1A Clinical Trial

September 22, 2026

PAB Establishes Clinical Advisory Committee

September 16, 2026

Ethics Approval Secured for Phase 1A Clinical Trial

August 27, 2026

Investor Presentation - TechKnow Invest Roadshow

July 26, 2026

Appendix 4C - Quarterly - 30 June 2026

July 21, 2026

Patrys Secures 50% Revenue Share in IP Commercialisation

July 12, 2026

Patrys advances RLS-2202 toward Phase 1 Clinical Trial

May 19, 2026

Appendix 4C - Quarterly - 31 March 2026

April 29, 2026

$3.2 million Placement to Advance Clinical Trials

April 19, 2026

Investor Presentation - Broker Meets Biotech

March 30, 2026

RLS-2201 Manufacturing and Regulatory Pathway Initiated

March 10, 2026

Appendix 4D - Half Year Accounts - 31 December 2025

February 26, 2026

Appointment of Chief Executive Officer

February 11, 2026

Appendix 4C - Quarterly - 31 December 2025

January 29, 2026

Investor Presentation

January 27, 2026

Completion of Acquisition and Board Appointments

January 27, 2026

Pipeline Expanded with Proprietary Injectable Antipsychotic

November 25, 2025

Trading Halt

November 23, 2025

Appendix 4C - Quarterly - 30 September 2025

October 29, 2025

Patrys Receives R&D Tax Incentive Refund

October 29, 2025

Notice of Annual General Meeting/Proxy Form

September 7, 2025

Appendix 4E - Preliminary Final Report

August 29, 2025

Appendix 4C - Quarterly - 30 June 2025

July 29, 2025

Entitlement Offer Prospectus

July 23, 2025

Non-Renounceable Entitlement Offer

July 23, 2025

Deed of Release entered into with CEO

June 16, 2025

Successful Placement and Board Changes

June 10, 2025

Reinstatement to Official Quotation

June 10, 2025

Suspension from Quotation

June 3, 2025

Appendix 4C - Quarterly - 31 March 2025

April 30, 2025

Appendix 4D - Half Year Accounts - 31 December 2024

February 21, 2025

Appendix 4C - Quarterly - 31 December 2024

January 29, 2025

Appendix 4C - Quarterly - 30 September 2024

October 29, 2024

PAT-DX1 clinical development update

October 1, 2024

PAT-DX1 GMP specification testing update

September 19, 2024

Appendix 4E and 2024 Annual Report

August 23, 2024

Further update on PAT-DX1 GMP manufacturing run

July 28, 2024

Appendix 4C - Quarterly - 30 June 2024

July 23, 2024

Update on GMP manufacturing run of PAT-DX1

June 30, 2024

Appendix 4C - Quarterly - 31 March 2024

April 29, 2024

Positive preclinical data for deoxymabs in vasculitis

April 8, 2024

Appendix 4D - Half Year Accounts - 31 December 2023

February 23, 2024

Appendix 4C - Quarterly - 31 December 2023

January 22, 2024

Older news releases →

Decks

The 5 newest of 43 decks. Every deck is listed under its year.